Thomas E Hutson, DO, PharmD

Heng DYC et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 2009;27(34):5794-9. Abstract

Lee C-H et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). ASCO 2020;Abstract 5008.

Rini BI et al. TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. ASCO Genitourinary Cancers Symposium 2021;Abstract 278.

Stukalin N et al. Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer 2018;2(1):31-6. Abstract

Thomas Powles, MBBS, MRCP, MD

Choueiri TK et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. ESMO 2020;Abstract 696O_PR.

Motzer R et al. Phase 3 trial of lenvatinib plus pembrolizumab or everolimus versus sunitinib monotherapy as a first-line treatment for patients with advanced renal cell carcinoma (CLEAR study). N Engl J Med 2021;384(14):1289-300. Abstract

Motzer RJ et al. Nivolumab + cabozantinib (NIVO + CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. ASCO Genitourinary Cancers Symposium 2021;Abstract 308.